Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.